Welichem Announces the Resignation of Lijuan Pang as a Director

Welichem Announces the Resignation of Lijuan Pang as a Director

BURNABY, BC, March 1, 2013 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Mrs. Lijuan Pang has resigned as a director of the Company effective March 1, 2013.

The Company has valued the contribution of Mrs. Pang as a director of the Company over the past one and half years and wishes her success in her future endeavours.

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer. For a more complete business and financial profile of the Company, interested parties are encouraged to visit the Company's website, www.welichem.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

SOURCE Welichem Biotech Inc.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.